<DOC>
	<DOCNO>NCT01884688</DOCNO>
	<brief_summary>The purpose study determine safety vivo persistence expansion autologous expansion autologous , ex vivo expanded-natural killer ( ENK ) cell .</brief_summary>
	<brief_title>UARK 2013-05 A Study Autologous Expanded Natural Killer Cell Therapy Asymptomatic Multiple Myeloma</brief_title>
	<detailed_description>To determine whether significant vivo expansion auto-ENK cell occur , define &gt; 4 fold increase absolute cluster differentiation 3 ( CD3 ) -cluster differentiation 56 ( CD56+ ) NK cell count/blood 7 day infusion pre-study baseline level safety ENK cell therapy research participant high-risk asymptomatic multiple myeloma ( AMM ) define gene expression profile ( GEP ) 70 gene score &gt; -0.26 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>The study population participant AMM see Myeloma Institute Research Therapy ( MIRT ) , continue followup standard clinical care test . Participants must diagnosis AMM define Staging Criteria ( Section 3.0 ) GEP70 score &gt; 0.26 . Participant ( male female ) race ethnicity must least 18 year age old 75 year age time registration . Participants must performance status 0 2 Zubrod criterion Participants must sign Institutional Review Board ( IRB ) approve informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization form . Must fit undergo leukapheresis ENK cell generation determine PI . Must suitable candidate insertion apheresis catheter . Participants unusual anatomy vascular anomaly prevent insertion apheresis catheter qualify . Patients must previous test result indicate adequate pulmonary function study ( PFT ) &gt; 50 % predict mechanical aspect ( FEV1 , force vital capacity ( FVC ) , etc ) diffusion capacity ( DLCO ) &gt; 50 % predict . Participants must receive prior treatment disease . Prior use bisphosphonates permit . No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 2 year . May history poorlycontrolled hypertension , diabetes mellitus , serious medical illness psychiatric illness could potentially interfere completion treatment accord protocol could consider exclusion criterion deem PI . Pregnant nursing woman may participate . Women childbearing potential must negative pregnancy test document within 10 14 day enrollment . Women/men reproductive potential may participate unless either agreed practice true abstinence , line prefer usual lifestyle participant . ( Periodic abstinence [ eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) OR begin TWO reliable method birth control : 1 highly effective method 1 additional effective method AT THE SAME TIME , least 28 day start study treatment 30 day last dose study treatment . Serologic evaluation use assess exposure syphilis , West Nile Virus , Chagas , cytomegalovirus ( CMV ) , Immunoglobulin G ( IgG ) , hepatitis B , C , HIV I II , human cell lymphoma virus ( HTLV ) I/II . Participants may hepatitis B C ( + ) unless positive due previous vaccination positive receive therapy negative hepatitis B C rapid test polymerase chain reaction ( RTPCR ) . An HIVI/II ( + ) HTLV1/II ( + ) participant reject medical ground . Participants serologically positive syphilis , West Nile Virus , Chagas , CMV , exclude treat active infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asymptomatic Multiple Myeloma</keyword>
	<keyword>Auto-ENK Cell Therapy</keyword>
	<keyword>Natural Killer Cells</keyword>
</DOC>